Thanks, Good joining morning us today. Allison. you thank for everyone and
we several execute, at that by I’m I absolutely to past company high excited performing are building have vision. to kind of organization our say a on at the started and Xeris. level continues again For delivering quarters, the entire reiterating what once
you that hope positive substantial and patient-centric, at intensely and focused Xeris away call a delivering focused our by build I continued from biopharma performance What continuing today’s self-sustaining everyone take on enterprise. for patients is to commercially remains
commercial in vision value partnerships believe pipeline I all our long-term products, result three development technology that business, growing and value. highly will added shareholder pillars our to contributing and targeted of multiple a are
of a of I with performance. increase of year. will a highlights the XX% start key We recorded XX% another second in million first quarter of quarter XXXX, revenue this and second record increase from from quarterly quarter $XX total
We at quarter continued the equivalents short-term with least our very of second third our This revenue support investments growth cash, consecutive cash $XX over quarter is healthy ended and year-over-year. position XX% to cash million growth. of in
the performance have outlook full-year XXXX on well. as we Based guidance rest our tightened for of and our year-to-date our XXXX,
net million total $XX and $XX to cash between revenue million, of of utilization and million. is $XXX Our XXXX $XX between million $XXX year-end revised XXXX guidance for of balance and million cash $XX million,
into point self-sustaining detail and company remain a a by to performance Steve financial some of we flow we be thereafter. on. to hit cash more will Importantly, track breakeven later get XXXX, on continue our year-end and will
and quarter increase generating increase strong growth, of over growing the and collectively a Recorlev quarter our Onto approximately our Gvoke, over revenue first All XX% in impressive business, of products. first net XXXX. products, product year last and million $XX second XX% showed three second quarter in pillar Keveyis the the commercial
time. break one in down it a at product me Let
totaling prescriptions Gvoke Gvoke, XX% record First, had net compared in second and another net of of increase quarter revenue, a XXXX. XX.X revenue to million quarter
period the Gvoke has for to app Total approximately and were XXXX XX% prescriptions record has week prescriptions last averaged growing increase over quarter hit quarter, second weekly most the per XX,XXX, all compared over recent quarter prescriptions a data. recently a year, and Throughout second XXXX first new XX% in XXXX. the of same the from time
Market outpace of majority growth continues products for consistent double-digits, to growth. other driving glucagon products is market the Gvoke back to the all by
share. to continue also capture market We
the in grew respectively. The of approximately market total XX% the prescriptions. XX% over to share and XX% ready-to-use end and of total of July new new glucagon At new Gvoke retail and market prescriptions now of represent prescriptions XX%, glucagon products
with We that now. bump prescriptions August occurs and are starting high, an July overall uptick late annually in we to by are believe season we accompanied in the growth. record weekly market during in And back-to-school the weekly latest see
inside build sales double-digit To now force. glucagon investing the on this and into year our growing of momentum in expansion we Gvoke’s going in XXXX, another modest later market, are
fourth adding the We of that force be of a quarter bringing in sales reps year, inside XX to will XX. total this
Gvoke in proven growth this have awareness, rather highly a be We and group gaining market generating fueling Gvoke productive, can quickly share.
last major launch milestone Gvoke Also, since over million shipped Gvoke have units you hit late may one its XXXX. a in have been week, seen
We of extremely are proud this achievement.
long of glucagon of increased event, until are sugar severe opportunity. who diabetes, risk surface the HypoPen. go a million as scratching a just are such with to blood low There XX a Gvoke this way we people carrying at are However, is ready-to-use
insulin use the major Endocrine address a manner Clinical the also low professionals potentially sulfony change event. be To to who advocate more, are is ADA, these societies, and guidelines and the situation patients other algorithms treated to Association professionals Endocrinology manage this blood professional have protected a severe motivate they to the should patients. in of do critical that some urea standard-of-care in healthcare sugar against life-threatening a their situation so for prescribed ready revised or all glucagon healthcare to and this the key Society, The the
emergency annually costs. due blood are deaths the of health low of the severe with associated the These available and avoidable ready-to-use glucagon are data, are products to on innovative department XXX,XXX as care tens latest XX,XXX sugar. Based thousands still new hospitalizations over there visits,
to On revenue period increase year. full and same net X.X quarter of launch, increase XXXX, the XX% the its over for generated quarter over Recorlev. since an of which second quarter first this an million in XXX% was in from of first Recorlev
first are grew steady We referrals over of increase patient patients XX%, the average respectively, with XX% on Recorlev pleased very number revenue quarter-over-quarter, the in drug and quarter. and
seeing impressive being therapy results valuing using is healthcare from positive that as increasingly more seeing treatment current referrals. and increasingly and that, post-surgery. drug first growing of some Recorlev are as patient’s a Cushing’s number means first are prescribed Even Recorlev a a therapy This for for we line Recorlev professionals syndrome
rates, rates rising the and Again, our with market. growth in on accelerating expected momentum the building referral conversion of
We fourth in will further quarter going momentum the of also in take invest the advantage our of into to approximately expanding core to XX Salesforce XXXX.
great therapy, Keveyis. of the year. despite an of fact Keveyis had revenue, the terms approved to has Moving generic quarter that and been since patients another in on there new referrals end last
$XX to period quarter of Second million, for over XXXX. revenue XX% Keveyis compared which represented in the same increase an was
XXXX. also have compared XX% grow continued rates of the referral to quarter second to Our approximately X% to
continue grew quarter XX% to patients we on the about second to the compared number Keveyis year. identify As average new last of patients,
Diclofenamide have have Paralysis. We patients. and and treat than maintain we taken support know measures the our takes to how patients To-date, seen process more Primary generics it impact to payer may Periodic
dosage. of There initiation value healthcare Xeris advocates therapy screening Connections patient authorization, mentors our titration through reimbursement and our is PPP Care on and heightened long focus to of a the providers team, the process effective of most support and to patients
pillar the study our XeriSol is and In of potentially enrolling now second we Phase patients quarter, weekly a subcu once the study about of XX% that in pipeline Onto second began development. business, injection, X enrolled. Levothyroxine,
have subjects stable enroll study study slow previously, at will and be said of dose we tests TX. thyroid for as Levothyroxine to a rather least laboratory to three-months As oral normal required be TSH the designed, with the such fully on
screened stability significant meet failed As chronic a number Levothyroxine, three-months. standard taking many oral we have expected, over for of subjects to the while
once associated clinical are challenges additional thyroid maintain sites replacement study completing order our research next to aim pace to of oral goal of with the with adding half we therapy, our year. our hormone need subcu of enhance we Further this which that unmet to in weekly address directly speaks evidence in first the currently to enrollment, the to the
if Phase for the X segment inform help have study, to from as pivotal a compete We $X Levothyroxine billion $X will a said believe Data market in FDA program. current approved, previously, will once prices. brand the at subcutaneous billion calculated we proposal weekly X to there are potential Phase our
development Merck, are and that Horizon our Xeris technology partnership business. all partner’s third various three to stages in of the have our or onto we meet XeriJect Regeneron expectations. and with exceed Now pillar, continue partnerships The
rounds several formulation for XeriJect First, completed Merck, of formulation have and we optimization.
stability XXX% their for have defined joint met of development upon have program We as the the and specifications delivered by plan. requirements work data all required and agreed molecule
formulation forward priorities. development pipeline asset move other into work clinical their our Merck preclinical expectations, exceeded chosen Although particular has not this their preclinical to given
Merck. impressed potential to work technology, explore and continue a opportunities have We our other to we They great relationship together. remain with with and team
note the also Xeris huge our a even Merck program as of was that benefit progressing, a collaboration. there would side this result I though to not program is
manufacturing timeline detailed that of achieved potential was deliverables One a the scale needed and be up. to validated plan for
worked and that incredibly successfully a XeriJect biologic forward As program engineering hard using of to plan all window own our future in our part collaborations. A team very batch, within manufacturing complete current development, the time first huge scale step up benefit that our can short material.
progress TEPEZZA. formulation the considerable optimization version Horizon, have continues and and work of of subcu For been made with
time We deliver meet of three target and are agreed stability. the months profile very will product positive we upon real confident
a will from payment Horizon. Once achieved, we receive million $X success
will will plan proceed license commercialization. they with to whether potential soon inform also development to whether Horizon expect thereafter option they us execute and as and further We their
in in announcing nominated Regeneron the March, two already has Regeneron molecules late Since the collaboration the program. platform first
to the molecules work second very soon. We are well work begin on on and two into first the formulation expect of the formulation
As creation. the of molecules Regeneron and long-term formulation unique value to development. XeriSol proposition we and partnerships value their the nominate reported formulation Each proprietary technology option previously, XeriJect highlight our of additional also has potential our for for capabilities
of as cash milestone to need a should shareholders demonstrate fund the our business expense This Through we to flow heard, that another take management, pillars away our continued the allocation of of before each operations. continuing biopharmaceutical you half perform. with breakeven we be and self without to additional can for XXXX first to sustaining prudent of disciplined equity resources revenue three quarter have capital that we you point our and just have Hopefully, growth, company great year-end. expect hit the growing,
call will I on our additional the turn over Steve quarter for details performance. financial to second
